GC Biopharma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, GC Biopharma sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
GC Biopharma: 3 sponsored US clinical trials, 2 recruiting.
GC Biopharma sponsors 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 1 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Sanfilippo Syndrome Type A, with 1 trials.
Upper-quartile sponsor footprint
GC Biopharma sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease
NCT06858397
Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)
NCT06567769
Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency
NCT04565015
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the GC Biopharma pipeline
2 recruiting of 3 indexed (67% open).
Phase mix: 1 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Sanfilippo Syndrome Type A (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
GC Biopharma: open-pipeline peers nationwide
Peers matched on 3 registered trials and 67% open enrollment, not the therapeutic-area sidebar.
GC Biopharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 67% open enrollment (± trial volume)
- Abbisko Therapeutics Co · 67% recruiting · 6 trials
- ABL Bio · 67% recruiting · 3 trials
- Accelerated Cure Project for Multiple Sclerosis · 67% recruiting · 3 trials
- Advanced Reconstructive Surgery Alliance · 67% recruiting · 3 trials
Related
What to do with this GC Biopharma page
3 registered trials is a research-attention snapshot, not an endorsement of GC Biopharma or any single study.
- 2 of GC Biopharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Sanfilippo Syndrome Type A is the condition GC Biopharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Sanfilippo Syndrome Type A trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. GC Biopharma pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.